Document:

EX-10.13

 Exhibit 10.13 

AMENDMENT NO. 1 
 TO

 STOCKHOLDERS’ AGREEMENT 

THIS AMENDMENT NO. 1 (this “Amendment”) to the Stockholders’ Agreement dated as of March 24, 2021 (the
“Agreement”), by and among Dermata Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the stockholders listed on Schedule A thereto (collectively, the
“Stockholders”), is made as of May 27, 2021 by and among the Company and the entities listed on the signature pages hereto. Each capitalized term used herein and not otherwise defined shall have the meaning ascribed to that
term in the Agreement. 
 RECITALS 

WHEREAS, the Company and each of the Stockholders are parties to the Agreement and now desire to amend the terms of the Agreement as
set forth below; 
 WHEREAS, pursuant to Section 12.6 of the Agreement, no amendment or modification of any provision of the
Agreement shall be effected without an instrument in writing signed by the (i) Company and (ii) Proehl Investment Ventures, LLC and Hale Biopharma Ventures, LLC (the “Requisite Holders”); and 

WHEREAS, the Company and the Requisite Holders are signatories to this Amendment. 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, and other consideration, the receipt and
adequacy of which is hereby acknowledged, the parties hereto agree as follows: 
 AGREEMENT 

1.    Amendment to Section 3.1. Section 3.1 of the Agreement shall be amended by deleting
it in its entirety and replacing it with the following : 
 “3.1    Restrictions on Transfers. 

(i) Transfers. No Stockholder may transfer all or any portion of Transfer Stock to a third party, without the prior
written consent of the Requisite Holders, which may be given or withheld by the Requisite Holders in their sole discretion. To the fullest extent permitted by law, any Proposed Stockholder Transfer not made in compliance with the requirements of
this Agreement shall be null and void ab initio, shall not be recorded on the books of the Company or its transfer agent and shall not be recognized by the Company. Each party hereto acknowledges and agrees that any breach of this Agreement would
result in substantial harm to the other parties hereto for which monetary damages alone could not 

 
adequately compensate. Therefore, the parties hereto unconditionally and irrevocably agree that any non-breaching party hereto shall be entitled to seek
protective orders, injunctive relief and other remedies available at law or in equity (including, without limitation, seeking specific performance or the rescission of purchases, sales and other transfers of Transfer Stock not made in strict
compliance with this Agreement). 
 (ii) Exemptions. Notwithstanding the foregoing or anything to the contrary herein,
the provisions of Section 3.1(i) shall not apply upon the transfer of Transfer Stock made for bona fide estate planning purposes, provided that (a) the Stockholder making a Proposed Stockholder Transfer shall deliver prior written
notice to the Company of such transfer, (b) such shares of Transfer Stock shall at all times remain subject to the terms and restrictions set forth in this Agreement and (c) such transferee shall, as a condition to such issuance, deliver a
counterpart signature page to this Agreement as confirmation that such transferee shall be bound by all the terms and conditions of this Agreement as a Stockholder (but only with respect to the securities so transferred to the transferee). 

2.    Amendment to Section 5.2(a). Section 5.2(a) of the Agreement shall be amended by
deleting it in its entirety and replacing it with the following: 
 “(a) (i) As the Lead Director (as defined below), one director
designated from time to time by the Requisite Holders which individual shall initially be David F. Hale; and (ii) as the two other directors designated from time to time by the Requisite Holders, which individuals shall initially be Gerald
Proehl and Wendell Wierenga, Ph.D.” 
 3.    Governing Law. This Amendment (and all matters arising herefrom
or relating hereto) shall be governed by, and its provisions construed and enforced in accordance with, the internal laws of the State of Delaware without reference to its principles regarding conflicts of laws. 

4.    Agreement. Wherever necessary, all other terms of the Agreement are hereby amended to be consistent with the
terms of this Amendment. Except as specifically set forth herein, the Agreement shall remain in full force and effect. 

5.    Counterparts; Facsimile. This Amendment may be executed in two (2) or more counterparts, each of which
shall be an original, but all of which together shall constitute one and the same instrument. This Amendment may also be executed via facsimile or electronic mail, either of which shall be deemed an original. 

  
 2 

 6.    Effect on Stockholders. Once executed by the Company and
the Requisite Holders, this Amendment shall be binding upon each current and future holder of any capital stock of the Company who is bound by or a party to the Agreement regardless of whether such holder has signed this Amendment. 

(Signature Pages Follow) 

  
 3 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written
above. 
  

			
	 THE COMPANY

	
	 DERMATA THERAPEUTICS, INC.

		
	By:	 	/s/ Gerald Proehl
	Name:	 	Gerald Proehl
	Title:	 	President and Chief Executive Officer

  
 Signature Page to Amendment
No. 1 to Dermata Therapeutics, Inc. Stockholders Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written
above. 
  

			
	 REQUISITE HOLDER

	
	 PROEHL INVESTMENT VENTURES, LLC

		
	By:	 	/s/ Gerald Proehl
	Name:	 	Gerald Proehl
	Title:	 	Managing Member

  
 Signature Page to Amendment
No. 1 to Dermata Therapeutics, Inc. Stockholders Agreement 

 IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written
above. 
  

			
	 REQUISITE HOLDER

	
	 HALE BIOPHARMA VENTURES, LLC

		
	By:	 	/s/ David Hale
	Name:	 	David Hale
	Title:	 	Managing Member

  
 Signature Page to Amendment
No. 1 to Dermata Therapeutics, Inc. Stockholders AgreementAPPLIFE DIGITAL SOLUTIONS, INC. 

SUBSCRIPTION AGREEMENT

 

APPLife Digital Solutions, Inc.

50 California St.

Suite 1500

San Francisco, CA 9411

 

 

RE:  APPLife Digital Solutions, Inc. Common Stock

 

Ladies and Gentlemen:

 

The undersigned investor in this Subscription Agreement hereby acknowledges receipt of the Prospectus, dated __________________, 2021, of APPLife Digital Solutions, Inc., a Nevada corporation (the “Company”), and subscribes for the following number of shares upon the terms and conditions set forth in the Prospectus.

 

The Investor agrees that this Subscription Agreement is subject to availability and acceptance by the Company.

 

The Investor hereby subscribes for ____________ shares of the Company’s common stock (“Common Stock”) at $_____ per share, for an aggregate purchase price of $____________. 

 

Payment of $____________ as payment in full of the purchase price is being made via wire transfer directly to the Company.  

 

If this subscription is rejected by the Company, in whole or in part, for any reason, all funds will be returned within three business days of the Company’s receipt of such funds, without interest or deduction of any kind.

  

 

Purchaser Information:

 

Printed Name:  ____________________________ 

 

Signature:____________________________ 

 

Date:____________________________ 

 

Address:____________________________ 

 

____________________________ 

 

____________________________ 

 

 

 

The foregoing Subscription is hereby accepted in full on behalf of APPLife Digital Solutions, Inc.

 

Date: ___________________

 

	APPLIFE DIGITAL SOLUTIONS, INC.:

	 

	 

	 

	 

	By:

	 

	 

	Name:

	Matthew Reid

	 

	Title:

	President & CEOExhibit
10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”) is dated as of _________, 2021, among Leader Capital Holdings Corp., a Nevada
Corporation (the “Company”), and ____________ (the “Purchaser”).

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(2) of the Securities Act of 1933, as amended
(the “Securities Act”) and Rule 504,Rule 506 and/or Regulation S promulgated thereunder, the Company desires to issue
and sell to the Purchaser, and the Purchaser desires to purchase from the Company, securities of the Company as more fully described
in this Agreement.

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:

 

ARTICLE
I

DEFINITIONS

 

1.1
Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings indicated in this Section 1.1:

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 144. With respect to the Purchaser, any investment fund or managed account
that is managed on a discretionary basis by the same investment manager as the Purchaser will be deemed to be an Affiliate of the Purchaser.

 

“Business
Day” means any day except Saturday, Sunday and any day that shall be a federal legal holiday or a day on which banking institutions
in the State of Nevada are authorized or required by law or other governmental action to close.

 

“Closing”
means the closing of the purchase and sale of the Common Stock pursuant to Section 2.1.

 

“Closing
Date” means the Business Day when this Agreement has been executed and delivered by the applicable parties thereto, and all
conditions precedent to the Purchaser’s obligations to pay the Purchase Price have been satisfied or waived.

 

“Commission”
means the Securities and Exchange Commission.

 

“Common
Stock” means the common stock of the Company, $0.0001 par value per share.

 

“Common
Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common
Stock, including without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible
into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“Liens”
means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

    	 

     

    

 

“Losses”
means a lien, charge, security interest, encumbrance, rights of first refusal, preemptive right or other restriction.

 

“Per
Share Purchase Price” equals $0.10

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such
as a deposition), whether commenced or threatened.

 

“Purchase
Price” means ______ Hundred Thousand Dollars ($_00,000.00).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to
time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“Securities
Act” means the Securities Act of 1933, as amended.

 

“Shares”
means the ________ shares of Common Stock issued or issuable to the Purchaser pursuant to this Agreement.

 

ARTICLE
II

PURCHASE
AND SALE

 

2.1
Closing. At the Closing, the Purchaser shall purchase from the Company, and the Company shall issue and sell to the Purchaser,
the Shares. Upon satisfaction of the conditions set forth in Section 2.2, the Closing shall occur at the offices of the Company, or such
other location as the parties shall mutually agree.

 

2.2
Closing Conditions.

 

(a)
At the Closing the Company shall deliver to the Purchaser:

 

(i)
this Agreement duly executed by the Company; and

 

(ii)
a certificate evidencing the Shares registered in the name of the Purchaser.

 

(b)
At the Closing the Purchaser shall deliver or cause to be delivered to the Company the following:

 

(i)
this Agreement duly executed by the Purchaser; and

 

(ii)
the Purchase Price by wire transfer to the account of the Company using the instructions attached hereto as Exhibit A.

 

(c)
All representations and warranties of the other party contained herein shall remain true and correct as of the Closing Date and all covenants
of the other party shall have been performed if due prior to such date.

 

    	2

     

    

 

ARTICLE
III

REPRESENTATIONS
AND WARRANTIES

 

3.1
Representations and Warranties of the Company. The Company hereby makes the following representations and warranties set forth
below to the Purchaser:

 

(a)
Subsidiaries. The Company has no direct or indirect subsidiaries.

 

(b)
Organization and Qualification. The Company is duly incorporated or otherwise organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization (as applicable), with the requisite power and authority to own
and use its properties and assets and to carry on its business as currently conducted.

 

(c)
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and otherwise to carry out its obligations hereunder or thereunder. The execution and delivery of this
Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary
action on the part of the Company and no further consent or action is required by the Company. This Agreement has been (or upon delivery
will be) duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding
obligation of the Company enforceable against the Company in accordance with its terms, subject to applicable bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium and similar laws affecting creditors’ rights and remedies generally and general
principles of equity.

 

(d)
Issuance of the Shares. The Shares are duly authorized and, when issued and paid for in accordance with this Agreement, will be
duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on
transfer provided for in this Agreement.

 

(e)
Capitalization. The authorized capital stock of the Company presently consists of 600,000,000 shares of Common Stock, $0.0001 par value,
and 200,000,000 shares of preferred stock, $0.0001 par value. The Company has 138,894,219 shares of Common Stock, and no shares of preferred
stock, issued and outstanding as of February 28, 2021. There are no other outstanding options, warrants, script rights to subscribe to,
calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exchangeable for,
or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts, commitments, understandings or
arrangements by which the Company is or may become bound to issue additional shares of Common Stock, or securities or rights convertible
or exchangeable into shares of Common Stock.

 

(f)
Litigation. There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of
the Company, threatened against or affecting the Company before or by any court, arbitrator, governmental or administrative agency or
regulatory authority (federal, state, county, local or foreign) which adversely affects or challenges the legality, validity or enforceability
of any of this Agreement or the Shares.

 

(g)
Reports; Financial Statements. The Company has filed all reports required to be filed by it under the Securities Act and the Exchange
Act, including pursuant to Section 13(a) or 15(d) thereof, for the twelve (12) months preceding the date hereof, (the foregoing materials
being collectively referred to herein as the “SEC Reports”) on a timely basis or has timely filed a valid extension of such
time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC
Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations
of the Commission promulgated thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact
or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading.

 

    	3

     

    

 

(h)
Shell Company Status. The Company is not a “shell company” (as such term is defined in Rule 12b-2 under the Exchange,
as amended (17 CFR 240.12b-2)).

 

(i)
Insurance. The Company maintains no insurance.

 

(j)
Private Placement. Assuming the accuracy of the Purchaser representations and warranties set forth herein, no registration under
the Securities Act is required for the offer and sale of the Shares by the Company to the Purchaser as contemplated hereby in accordance
with the terms of this Agreement.

 

3.2
Representations and Warranties of the Purchaser. The Purchaser represents and warrants as of the date hereof and as of the Closing
Date to the Company as follows:

 

(a)
Organization; Authority. If the Purchaser is an entity, the Purchaser is an entity duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization with full right, corporate or partnership power and authority to enter
into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations thereunder. The execution,
delivery and performance by the Purchaser of the transactions contemplated by this Agreement have been duly authorized by all necessary
corporate action on the part of the Purchaser. This Agreement, to which it is party has been duly executed by the Purchaser, and when
delivered by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of the Purchaser,
enforceable against it in accordance with its terms except (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally,
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.

 

(b)
Investment Intent. The Purchaser understands that the Shares are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Shares as principal for its own account for investment
purposes only and not with a view to or for distributing or reselling such Shares or any part thereof, has no present intention of distributing
any of such Shares and has no arrangement or understanding with any other persons regarding the distribution of such Shares. The Purchaser
is acquiring the Shares hereunder in the ordinary course of its business. The Purchaser does not have any agreement or understanding,
directly or indirectly, with any Person to distribute any of the Shares.

 

(c)
Purchaser Status. At the time the Purchaser was offered the Shares, it was, and at the date hereof it is an “accredited
investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act. The Purchaser is not required
to be registered as a broker-dealer under Section 15 of the Exchange Act.

 

(d)
Experience of the Purchaser. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Shares, and has so evaluated the merits and risks of such investment. The Purchaser is able to bear the economic risk of an investment
in the Shares and, at the present time, is able to afford a complete loss of such investment.

 

    	4

     

    

 

(e)
General Solicitation. The Purchaser is not purchasing the Shares as a result of any advertisement, article, notice, general solicitation
or other communication regarding the Shares published in any newspaper, magazine or similar media or broadcast over television or radio
or presented at any seminar or any other general solicitation or general advertisement.

 

(f)
Residence. The office or offices of the Purchaser in which its investment decision was made is located at the address or addresses
of the Purchaser set forth on the signature page hereto.

 

(g)
Rule 144. Subject to Section 4.1(a), the Purchaser acknowledges and agrees that the Shares are “restricted securities”
as defined in Rule 144 promulgated under the Securities Act as in effect from time to time and must be held indefinitely unless they
are subsequently registered under the Securities Act or an exemption from such registration is available. The Purchaser has been advised
or is aware of the provisions of Rule 144, which permits limited resale of shares purchased in a private placement subject to the satisfaction
of certain conditions, including, among other things: the availability of certain current public information about the Company, the resale
occurring following the required holding period under Rule 144 and the number of shares being sold during any three-month period not
exceeding specified limitations.

 

ARTICLE
IV

OTHER
AGREEMENTS OF THE PARTIES

 

4.1
Transfer Restrictions.

 

(a)
The Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Shares other
than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of the Purchaser, the Company may
require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to
the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of such transferred Shares under the Securities Act. As a condition of transfer, any such transferee shall
agree in writing to be bound by the terms of this Agreement and shall have the rights of the Purchaser under this Agreement.

 

(b)
The Purchaser agrees to the imprinting, so long as is required by this Section 4.1(b), of the following legend on any certificate evidencing
Shares:

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS.

 

(c)
The Purchaser agrees that the removal of the restrictive legend from certificates representing Shares as set forth in this Section 4.1
is predicated upon the Company’s reliance that the Purchaser will sell any Shares pursuant to either the registration requirements
of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom.

 

    	5

     

    

 

ARTICLE
V

MISCELLANEOUS

 

5.1
Fees and Expenses. Except as otherwise set forth in this Agreement, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement. The Company shall pay all stamp and other taxes and duties levied in connection
with the sale of the Shares.

 

5.2
Entire Agreement. This Agreement, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such
matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

5.3
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number set forth on the signature pages attached hereto prior to 5:00 p.m. (New York time) on a Business
Day, (b) the next Business Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile
number set forth on the signature pages attached hereto on a day that is not a Business Day or later than 6:00 p.m. (New York time) on
any Business Day, (c) the second Business Day following the date of mailing, if sent by U.S. nationally recognized overnight courier
service, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
shall be as set forth on the signature pages attached hereto.

 

5.4
Amendments; Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case
of an amendment, by the Company and the Purchaser or, in the case of a waiver, by the party against whom enforcement of any such waiver
is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a
continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.

 

5.5
Construction. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the
parties to express their mutual intent, and no rules of strict construction will be applied against any party.

 

5.6
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of the Purchaser. The Purchaser may assign its rights under this Agreement to any Person to whom the Purchaser assigns or transfers any
Shares.

 

5.7
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4.5.

 

    	6

     

    

 

5.8
Governing Law; Venue; Waiver of Jury Trial. All questions concerning the construction, validity, enforcement and interpretation
of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without
regard to the principles of conflicts of law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state
and federal courts sitting in the County of New York, New York, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of this Agreement), and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction
of any such court, that such suit, action or proceeding is improper or inconvenient venue for such proceeding. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. The parties hereby waive
all rights to a trial by jury. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then
the prevailing party in such action or proceeding shall be reimbursed by the other party for its attorney’s fees and other costs
and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

 

5.9
Survival. The representations, warranties and covenants contained herein shall survive the Closing and delivery and/or exercise
of the Shares, as applicable.

 

5.10
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party,
it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with
the same force and effect as if such facsimile signature page were an original thereof.

 

5.11
Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such
substitute provision in this Agreement.

 

IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

	 	Leader
    Capital Holdings Corp.
	 	 
	 	By:	          
	 	Yi-Hsiu
    Lin
	 	Title:
    CEO 
	 	 
	 	Address
    for Notice:
	 	 
	 	Room
    2708-09, Metropolis Tower,

    10
    Metropolis Drive,

    Hung
    Hom, Hong Kong

 

[SIGNATURE
PAGE FOR PURCHASER FOLLOWS]

 

    	7

     

    

 

[PURCHASER’S
SIGNATURE PAGE]

 

IN
WITNESS WHEREOF, the undersigned has caused this Securities Purchase Agreement to be duly executed by its authorized signatories as of
the date first indicated above.

 

	[PURCHASER]	 
	____________	 
	 	 	 
	By:	             	 
	Name:
    	 	 
	 	 	 
	Address
    for Notice:	 
	 	 	 
	Taiwan	 

 

 

 

    	8

     

    

 

Exhibit
A

 

Wire
Transfer Instructions

 

    	9

     

    

 

EXHIBIT
B

 

SCHEDULE
OF PURCHASERS

 

    	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]